Detail of "3965-17-1"

Reference

Enhanced steroidal drug delivery in transdermal systems

Enhanced steroidal drug delivery in transdermal systems. Houze, David; Nguyen, Viet (Noven Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2002102390 A1 27 Dec 2002, 49 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K031-56. ICS: A61K031-55; A61K031-415; A61K031-40. APPLICATION: WO 2002-US16579 18 Jun 2002. PRIORITY: US 2001-PV298381 18 Jun 2001; US 2001-948107 7 Sep 2001. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 2 A compn. for transdermal administration resulting from an admixt. includes a therapeutically effective amt. of a drug that includes a parent drug and a prodrug and a carrier, wherein the parent drug and prodrug are individually present in an amt. sufficient for a pharmacol. effect. The admixt. include: a therapeutically effective amt. of a steroid and a steroid deriv. and a carrier for the steroid. The steroid and the corresponding deriv. are present in a wt. ratio of to 1:10 steroid-corresponding steroid deriv. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid deriv. is a steroidal ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive. In another preferred embodiment, the parent drug is an ACE inhibitor such as ramipril and the prodrug is an ACE inhibitor prodrug such as ramipril Et and/or Me esters. Thus, a transdermal delivery system contained norethindrone 1.2, estradiol 0.9, norethindrone acetate 2. 3965-17-1 which is the cas registry number of one of substances is just one of reagents here.5, VA-64 15.0, GMS-737 (acrylic PSA), oleic acid 3.0, dipropylene glycol 9.0, and Bio-PSA-7-4603 63.4%. .